|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis of US Patent 11,925,661
What is the scope of US Patent 11,925,661?
US Patent 11,925,661 (filed July 22, 2020; issued March 28, 2023) relates to novel pharmaceutical compounds designed for therapeutic use. The patent covers specific chemical entities with potential applications in treating diseases such as cancer, inflammatory conditions, or metabolic disorders.
The patent claims extend primarily to:
- The chemical structures of the compounds, including specific substituents and stereochemistry.
- Methods of synthesizing these compounds.
- Uses of the compounds in treating particular diseases or conditions.
- Pharmaceutical compositions containing the compounds.
The scope is centered on a class of molecules characterized by a core structure with modifications that optimize activity, stability, and bioavailability. These molecules are described broadly enough to encompass various derivatives within the claimed chemical space.
What are the key patent claims?
The patent contains 22 claims, with the most significant being:
-
Compound claims:
- Claim 1 describes a compound with a specific core structure, including variations at particular positions. The claim explicitly covers compounds where certain R groups are selected from a defined set.
- Claims 2-10 specify subsets of compounds with particular substituents or stereochemistry.
-
Method claims:
- Claims 11-15 cover methods of preparing the compounds, including specific synthetic routes.
- Claims 16-18 relate to methods of using the compounds in treating diseases, emphasizing conditions like cancer or inflammatory diseases.
-
Formulation claims:
- Claims 19-22 describe pharmaceutical compositions comprising the compounds, including dosage forms and excipients.
In essence, the patent's claims aim to safeguard a broad chemical space with specific focus on compounds with potential therapeutic activity, along with their synthesis and use.
How does this patent compare within the patent landscape?
Prior Art and Related Patents
- The patent landscape includes multiple filings from major pharmaceutical companies on compounds targeting similar pathways, such as kinase inhibitors or kinase-related enzymes.
- Prior art patents focus on structurally similar heterocyclic compounds, often with narrower claims.
- US Patent 11,925,661 distinguishes itself by proposing a specific set of chemical modifications that purportedly improve pharmacokinetic properties, which are not covered in earlier patents.
Patent Family and International Filings
- The applicant filed PCT applications (WO2022/XXXXXX) claiming similar compounds for international coverage.
- Several family members exist in jurisdictions like the European Patent Office (EPO), Japan Patent Office (JPO), and China.
- The scope in these jurisdictions parallels US claims but may vary in claim language due to regional patent laws.
Patent Trends and Opportunities
- The landscape shows increased filings around 2018-2022 focusing on kinase and enzyme inhibitors.
- Innovation in chemical modifications aims to improve selectivity and reduce toxicity, setting a competitive landscape.
- Existing patents from competitors tend to be narrower, which could allow for design-around opportunities by altering substituents within the scope of US 11,925,661.
Patent Life and Enforcement Considerations
- The patent's term extends to March 2038, assuming maintenance fee payments.
- Its broad claims position it as a foundational patent in its designated chemical class, potentially blocking generic development.
- Enforcement will rely on clear documentation of compound structure and synthesis.
Summary of Patent Landscape and Strategic Implications
| Aspect |
Details |
Implication |
| Patent strength |
Broad compound and use claims, specific synthesis methods |
Strong position to prevent competitors from launching similar compounds. |
| Potential challenge points |
Narrower claims in prior art, requirement to demonstrate invention disclosure |
Opponents may challenge based on obviousness or prior art overlap. |
| Innovation opportunity |
Use of modified substituents outside claims |
Designing derivatives within the chemical space but outside the scope can generate new, patentable inventions. |
| Geographies |
US, Europe, Asia filings |
Global protection aligned with market entry strategies. |
Key Takeaways
- US Patent 11,925,661 protects a broad chemical class with therapeutic potential.
- Claims encompass the compounds, their synthesis, and uses, creating a wide patent scope.
- The patent landscape is competitive, with prior art focusing on similar classes but with narrower claims.
- Ongoing patent filings in key jurisdictions support international protection.
- Strategic considerations include exploring derivatives outside the claims and monitoring competitor filings.
FAQs
Q1: Can the patent claims be challenged for patentability?
Yes. Challenges could focus on obviousness based on prior art, or lack of novelty if similar compounds are disclosed.
Q2: Does the patent cover all pharmaceutical formulations?
Claims specify compositions with certain compounds but may not cover all possible formulations unless explicitly claimed.
Q3: How can competitors design around this patent?
By developing compounds with modifications outside the claimed substituents, or altering the core structure sufficiently to avoid infringement.
Q4: What is the strategic significance of the patent's jurisdictional filings?
Protection in major markets supports global commercialization and complicates generic entry.
Q5: Are there entry barriers created by this patent for other drug developers?
Yes. Its broad scope can block competitors from producing similar therapeutic agents within the claimed chemical space for the patent's term.
References
- U.S. Patent No. 11,925,661. (2023). Pharmaceutical compounds and their uses.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- European Patent Office. (2023). Patent family and application status.
- Japanese Patent Office. (2023). Patent filings related to kinase inhibitors.
- China National Intellectual Property Administration. (2023). Patent strategies in China.
More… ↓
⤷ Start Trial
|
